SLIDE 13 NOTES: No notes.
Gold MR, Siebel JE, Russell LB, Weinstein MC, Editors. 1996. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. 1993. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 328(19): 1365–1371.
Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. 2000. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 343(22):1603–1607.
Mandel JS, Church TR, Ederer F, Bond JH. 1999. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 91(5):434–437.
Vijan S, Hwang EW, Hofer TP, Hayward RA. 2001. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 111(8):593–601.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Appendix H Overview of the Vijan Colorectal Cancer Screening Model--Sandeep Vijan, M.D., M.S. ."
Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: